• Login
    View Item 
    •   Home
    • Centers & Institutes
    • Georgia Cancer Center
    • Georgia Cancer Center: Faculty Research and Presentations
    • View Item
    •   Home
    • Centers & Institutes
    • Georgia Cancer Center
    • Georgia Cancer Center: Faculty Research and Presentations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Scholarly CommonsCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    About

    AboutCreative CommonsAugusta University LibrariesUSG Copyright Policy

    Statistics

    Display statistics

    Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    CDI2012-124187.pdf
    Size:
    568.2Kb
    Format:
    PDF
    Download
    Authors
    Zhou, Gang
    Levitsky, Hyam
    Issue Date
    2012-05-31
    URI
    http://hdl.handle.net/10675.2/801
    
    Metadata
    Show full item record
    Abstract
    The past decade has witnessed the evolvement of cancer immunotherapy as an increasingly effective therapeutic modality, evidenced by the approval of two immune-based products by the FDA, that is, the cancer vaccine Provenge (sipuleucel-T) for prostate cancer and the antagonist antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) ipilimumab for advanced melanoma. In addition, the clinical evaluations of a variety of promising immunotherapy drugs are well under way. Benefiting from more efficacious immunotherapeutic agents and treatment strategies, a number of recent clinical studies have achieved unprecedented therapeutic outcomes in some patients with certain types of cancers. Despite these advances, however, the efficacy of most cancer immunotherapies currently under clinical development has been modest. A recurring scenario is that therapeutic maneuvers initially led to measurable antitumor immune responses in cancer patients but ultimately failed to improve patient outcomes. It is increasingly recognized that tumor cells can antagonize therapy-induced immune attacks through a variety of counterregulation mechanisms, which represent a fundamental barrier to the success of cancer immunotherapy. Herein we summarize the findings from some recent preclinical and clinical studies, focusing on how tumor cells advance their survival and expansion by hijacking therapy-induced immune effector mechanisms that would otherwise mediate their destruction.
    Citation
    Clin Dev Immunol. 2012 May 31; 2012:124187
    ae974a485f413a2113503eed53cd6c53
    10.1155/2012/124187
    Scopus Count
    Collections
    Georgia Cancer Center: Faculty Research and Presentations

    entitlement

    Related articles

    • Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells.
    • Authors: Kim SJ, Ha GH, Kim SH, Kang CD
    • Issue date: 2014
    • Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    • Authors: Maccalli C, Parmiani G, Ferrone S
    • Issue date: 2017 Apr
    • Current perspectives on immunotherapy.
    • Authors: Weber JS
    • Issue date: 2014 Oct
    • The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    • Authors: Workenhe ST, Verschoor ML, Mossman KL
    • Issue date: 2015
    • Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?
    • Authors: Malmberg KJ
    • Issue date: 2004 Oct
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.